Currently,the treatment of chronic periodontitis (CP) still has challenges. This study aimed to identify novel drug targets for the treatment of chronic periodontitis in the druggable genome usung the Mendelian randomization (MR) method.In this study,based on the list of 4479 drug gene targets,overlapping genes were selected in blood expression Quantitative Trait Loci(eQTL), which were then subjected to Two-Sample MR(TSMR) and validated Fusion Transcriptome-Wide Association Study(TWAS) with data from the Genome-Wide Association Study(GWAS) of CP to confirm drug genes genetically associated with CP and tested for multiplicity of effects using Summary-data-based Mendelian randomization(SMR) analysis and colocalisation. Finally, Phenome-Wide association study(PheWAS) was executed on the identified drug targets.We applied SMR,TSMR,Fusion TWAS,and a series of manners of co-localisation to assess the genetic association between drugable targets and CP. In conclusion,Metalloproteinase 25(MMP25)was considered the most promising drug target,in addition to which we maintained some confidence in TNFRSF18,CDC25B,STK10 and ACVR2B.Finally,the PheWAS-MR results showed that the possible side effects of applying MMP25 inhibitors were Otitis externa as well as some metabolic disorders,among others.In summary,we identified five potential CP drug targets using TSMR,Fusion TWAS,SMR,and co-localisation a series of methods,of which MMP25 passed all the tests.Such discovery offered an academic basis for future CP drug development and reduce drug development time and economic costs to some extent.

The authors have declared that no competing interests exist.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The GWAS dataset relevantto this study was sourced from a public database,and informed consent was obtained from thestudy subjects in the original research.Therefore,ethical committee approval was not requiredfor this particular aspect of the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes